LEADER 01213nam 2200337Ia 450 001 996387050403316 005 20200824132742.0 035 $a(CKB)4940000000082916 035 $a(EEBO)2240895579 035 $a(OCoLC)ocm18177012e 035 $a(OCoLC)18177012 035 $a(EXLCZ)994940000000082916 100 $a19880706d1661 uy | 101 0 $aeng 135 $aurbn||||a|bb| 200 10$aGods soveraignity, His Sacred Majesties supremacy, the subjects duty$b[electronic resource] $easserted in a sermon, preached before His Majesties high commissioner, and the honourable Parliament of the kingdom of Scotland, at Edinburgh, the 31. of March, 1661 /$fby Mr. Hugh Blair .. 210 $aGlasgow $cPrinted by Robert Sanders ...$d1661 215 $a[4], 19 p 300 $aReproduction of original in the British Library. 330 $aeebo-0018 606 $aSermons, English$y17th century 615 0$aSermons, English 700 $aBlair$b Hugh$0203757 801 0$bEAI 801 1$bEAI 801 2$bUMI 801 2$bWaOLN 906 $aBOOK 912 $a996387050403316 996 $aGods soveraignity, His Sacred Majesties supremacy, the subjects duty$92399861 997 $aUNISA LEADER 03667nam 2200565 450 001 9910821000603321 005 20200520144314.0 010 $a1-119-06084-2 010 $a1-119-06080-X 010 $a1-119-06072-9 035 $a(CKB)4330000000008245 035 $a(DLC) 2016034128 035 $a(Au-PeEL)EBL4745624 035 $a(CaPaEBR)ebr11300198 035 $a(CaONFJC)MIL978150 035 $a(PPN)196411955 035 $a(MiAaPQ)EBC4745624 035 $a(OCoLC)954037554 035 $a(EXLCZ)994330000000008245 100 $a20160715h20172017 uy| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aAntibody-drug conjugates $efundamentals, drug development, and clinical outcomes to target cancer /$fedited by Kenneth J. Olivier Jr. and Sara A. Hurvitz 210 1$aHoboken, New Jersey :$cJohn Wiley & Sons, Incorporated,$d[2017] 210 4$dİ2017 215 $a1 online resource (566 pages) $ccolor illustrations 311 $a1-119-06068-0 320 $aIncludes bibliographical references and index. 327 $aTypical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han. 606 $aAntibody-toxin conjugates 606 $aMonoclonal antibodies 606 $aAntineoplastic agents 606 $aTumors$xTreatment 615 0$aAntibody-toxin conjugates. 615 0$aMonoclonal antibodies. 615 0$aAntineoplastic agents. 615 0$aTumors$xTreatment. 676 $a615.7/98 702 $aOlivier$b Kenneth J.$cJr.,$f1968- 702 $aHurvitz$b Sara A.$f1970- 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910821000603321 996 $aAntibody-drug conjugates$92231062 997 $aUNINA